evipedia.ai
← Back

Melatonin for Health & Longevity

Evidence Review created on 08/26/2026 using AI4L / Opus 5

Also known as: N-acetyl-5-methoxytryptamine, 5-methoxy-N-acetyltryptamine

Motivation

Melatonin is a hormone the pineal gland, a small structure deep in the brain, releases when light fades. It is the body’s main night signal: it tells organs and cells that darkness has begun and helps set when sleep arrives. The same molecule is also made inside cells throughout the body, where it appears to protect them from chemical damage.

Sold as a prescription medicine in much of Europe and as an inexpensive supplement in the United States, melatonin has been used for sleep since the early 1990s, and sales have climbed steadily since. Attention widened once researchers reported that the nightly rise weakens in many older people, and that the molecule also touches blood pressure, blood sugar handling, and how cells repair themselves.

This review examines what controlled human research shows about melatonin taken as a supplement: which effects hold up, at what doses and timing, where findings pull in opposite directions, and what harms have been recorded. It also examines how far laboratory and animal results carry over to people, the quality of products on the market, and the questions that remain open.

Benefits - Risks - Protocol - Conclusion

This section lists high-level expert commentary and overview material on melatonin that frames the evidence rather than reporting a single trial.

  • Melatonin - Rhonda Patrick

    A written overview tying melatonin’s circadian and antioxidant roles together, with dose and timing figures pulled from recent meta-analyses and a section on whether supplementing suppresses the body’s own output.

  • Concerning findings on melatonin content in over-the-counter supplements - Peter Attia

    A short critical read of the analytical work on gummy products, and the clearest statement of the practical case for using melatonin sparingly rather than nightly.

  • Sleep Toolkit: Tools for Optimizing Sleep & Sleep-Wake Timing - Andrew Huberman

    A podcast episode placing melatonin inside a full sleep and circadian protocol, and arguing that typical supplement doses are far above what the timing signal requires.

  • A Case for Higher-Dose Melatonin - William Faloon

    The most developed argument for doses well above 10 mg, useful as the strongest opposing case. Its publisher sells melatonin products, so the piece carries a direct commercial interest.

  • Melatonin: Benefits, Side Effects, and Research - Larisa Sheloukhova

    A longevity-focused overview that maps melatonin onto the hallmarks of aging and is candid that most of that mapping rests on cell and animal work.

Grokipedia

  • Melatonin

    Covers biosynthesis, receptor and non-receptor mechanisms, measurement methods, plasma concentration ranges, and therapeutic uses, including a candid section on where guideline bodies advise against melatonin.

Examine

  • Melatonin

    Grades melatonin against 36 conditions from pooled trial data and carries a structured safety section covering side effects, drug interactions, pregnancy, and anti-doping status.

ConsumerLab

  • Melatonin Supplements Review

    Reports independent laboratory assay results and cost-per-milligram comparisons for 20 approved products, and flags how far label claims have historically drifted from measured content.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that carry the most weight for melatonin’s benefits and for its principal risk, its side-effect burden.

Mechanism of Action

Melatonin acts through two receptors, MT1 and MT2 (docking sites for melatonin on cell surfaces), concentrated in the suprachiasmatic nucleus, the brain’s master clock. MT1 activation dampens the clock’s wake-promoting output; MT2 activation shifts the clock’s phase, advancing or delaying it depending on when the dose lands relative to the body’s own rise. This phase-shifting action, not sedation, is the dominant effect at low doses. Melatonin also lowers core body temperature and increases the availability of GABA (gamma-aminobutyric acid, the brain’s main calming signal), both favouring sleep onset.

A second, receptor-independent mechanism is proposed: melatonin is small and fat-soluble enough to enter mitochondria, the structures that generate cellular energy, where it neutralises reactive oxygen species (damaging by-products of that process) and activates Nrf2 (a switch that turns on a cell’s antioxidant genes) while suppressing NF-κB (a master switch for inflammation). Which mechanism explains melatonin’s non-sleep effects is contested. One camp holds the antioxidant action requires tissue concentrations far above those oral dosing reaches; the other holds mitochondrial melatonin is made locally and supplementation tops up a depleted pool.

Pharmacologically, melatonin activates MT1 and MT2 selectively, with negligible affinity for other receptors. Only 3–15% of an oral dose reaches the bloodstream; much is broken down by the liver first. Being fat-soluble, it distributes widely, crossing the blood–brain barrier and the placenta. Immediate-release melatonin’s elimination half-life is short, roughly 40–60 minutes. Metabolism runs almost entirely through CYP1A2 (a liver enzyme that also clears caffeine) to 6-hydroxymelatonin, which is excreted in urine.

Historical Context & Evolution

Melatonin was isolated in 1958 by dermatologist Aaron Lerner, who was hunting for a pineal factor that lightened amphibian skin. The name records that origin: it blanched frog skin by opposing melanocyte-stimulating hormone. Its original intended use was therefore dermatological, and it had nothing to do with sleep.

Through the 1960s and 1970s researchers established that pineal output is suppressed by light and rises in darkness, making melatonin a readable output of the body clock. Work at the Massachusetts Institute of Technology in the 1980s showed that milligram and sub-milligram oral doses shortened sleep latency and shifted circadian phase, far below the doses soon sold.

Interest widened to health optimization in the mid-1990s. Pineal transplantation experiments reported that grafting young pineal tissue into old mice extended their lifespan, and rodent studies reported that melatonin in drinking water lengthened survival while lowering markers of oxidative damage. Bestselling books and a US supplement boom followed. The findings themselves were more equivocal than the books: one careful long-term study found that melatonin extended lifespan in female mice and simultaneously increased spontaneous tumour incidence, leading its own authors to caution against long-term use as a longevity intervention.

Scientific opinion has since moved toward treating melatonin as a clock-shifting agent rather than a broad longevity agent, and toward lower doses. What changed was the accumulation of human trials showing modest sleep effects, alongside continued animal and mechanistic work that still supports broader roles. The lifespan question in mammals remains open in both directions.

Expected Benefits

High 🟩 🟩 🟩

Faster Sleep Onset and Better Sleep Quality

Melatonin shortens the time taken to fall asleep and modestly improves rated sleep quality. The mechanism is circadian phase advance plus a small direct sleep-permitting effect, not sedation. The evidence is a meta-analysis of 19 randomized trials in 1,683 people with primary sleep disorders, a dose-response meta-analysis of 26 trials, and a meta-analysis of sleep-quality scores across mixed populations. The absolute gain is small and smaller than prescription sleep medications deliver; it does not fade with continued use.

Magnitude: Sleep onset latency reduced by a weighted mean of 7.06 minutes (95% confidence interval, the range in which the true value most likely lies, 4.37–9.75) and total sleep time increased by 8.25 minutes; effect grows with dose and with earlier administration, peaking near 4 mg taken three hours before bedtime.

Lower Nighttime Blood Pressure

Controlled-release melatonin lowers blood pressure during sleep, the period whose readings track cardiovascular events most closely. The proposed mechanism is MT2-mediated widening of blood vessels plus reduced night-time nervous-system activity. The evidence is a meta-analysis of seven randomized trials and a later meta-analysis of five trials pooling overall systolic and diastolic readings. Immediate-release melatonin does nothing here. Two authors of the earlier meta-analysis were employed by the manufacturer of prescription prolonged-release melatonin, a direct commercial interest in the result.

Magnitude: Controlled-release melatonin reduced nocturnal systolic pressure by 6.1 mmHg (95% confidence interval −10.7 to −1.5) and diastolic by 3.5 mmHg (−6.1 to −0.9); fast-release preparations produced −0.3 and −0.2 mmHg, neither distinguishable from placebo.

Fewer Delirium Episodes Around Surgery and Hospitalization

Delirium after major surgery predicts later cognitive decline, which makes it relevant to anyone planning an elective procedure. Melatonin and drugs that mimic it reduce its incidence, probably by preserving the sleep-wake cycle in disrupted environments. The evidence is a meta-analysis of 14 randomized trials in 1,712 patients and a later meta-analysis restricted to older hospitalized patients. Benefit was confined to surgical and intensive-care patients; medical inpatients showed none, and length of stay and mortality were unchanged.

Magnitude: Delirium incidence relative risk 0.61 (the risk on melatonin divided by the risk on control; 95% confidence interval 0.42–0.89), corresponding to a 49% risk reduction in surgical patients and 34% in intensive-care patients, with no significant reduction in general medical inpatients.

Less Anxiety Before and After an Operation

Melatonin given before an operation lowers anxiety in the hours beforehand and, less strongly, in the recovery period. The proposed mechanism is mild sedation plus increased availability of the brain’s main calming signal rather than a direct anti-anxiety drug action. The evidence is a Cochrane meta-analysis of 27 randomized trials in 2,319 adults. Certainty is graded moderate rather than high because no contributing trial was at low risk of bias throughout, and the postoperative effect is much smaller than the preoperative one.

Magnitude: Preoperative anxiety fell by 11.69 points on a 0–100 visual analogue rating scale (95% confidence interval −13.80 to −9.59) against placebo, with no meaningful difference against midazolam and similar benzodiazepines (a class of prescription sedatives) (0.78, −2.02 to 3.58).

Medium 🟩 🟩

Relief of Jet Lag After Eastward Travel

Melatonin taken near local bedtime at the destination speeds the clock’s realignment after crossing several time zones. The mechanism is direct phase advance of the body clock. The evidence is a Cochrane systematic review of ten randomized trials in passengers, aircrew and military personnel. It is graded Medium rather than High because outcomes were subjective jet-lag ratings on non-standardised scales in small trials, and the review has not been updated since 2002.

Magnitude: Number needed to treat (the count of travellers who must take it for one to benefit) was 2. Nine of ten trials found benefit after crossing five or more time zones; doses of 0.5–5 mg were similarly effective, and doses above 5 mg added nothing.

Reduced Migraine Frequency

Melatonin reduces monthly migraine days, plausibly through the same hypothalamic circuits that link migraine to sleep timing. The evidence is a randomized trial of 178 adults comparing 3 mg melatonin, 25 mg amitriptyline and placebo and a meta-analysis pooling the controlled trials. Melatonin beat placebo and matched amitriptyline with better tolerability and weight loss rather than weight gain. The pooled evidence base is only three trials, and melatonin showed no advantage over existing preventives.

Magnitude: Mean reduction of 2.7 migraine days per month with melatonin versus 1.1 with placebo; pooled responder odds ratio 1.84 (95% confidence interval 1.08–3.14), where the odds ratio compares the odds of responding on melatonin against control.

Milder Irritable Bowel Syndrome Symptoms

Melatonin lowers overall symptom severity in irritable bowel syndrome, a disorder of gut pain and altered bowel habit without structural damage. The proposed mechanism is a direct effect on gut smooth-muscle motility, since melatonin is made in the gut lining as well as the pineal gland. The evidence is a meta-analysis of four randomized trials in 115 patients. Pain and quality of life improved alongside severity, while abdominal distension and sleep quality did not; the pooled sample is small.

Magnitude: Overall symptom severity improved with a standardised effect size (Hedges’ g, the average gap between groups expressed in standard deviations) of 0.746 (95% confidence interval 0.401–1.091) against placebo, with the same result in the subgroup taking no concurrent medication.

Improved Liver Enzymes in Fatty Liver Disease ⚠️ Conflicted

In non-alcoholic fatty liver disease, the commonest liver abnormality in metabolically healthy-looking adults, melatonin improves several liver enzyme markers. The proposed mechanism is reduced hepatic oxidative stress and inflammation. The evidence is a meta-analysis of five randomized clinical trials. The pattern is inconsistent: gamma-glutamyltransferase and alkaline phosphatase (liver enzymes that rise when liver cells are stressed) fell, alanine aminotransferase and aspartate aminotransferase (two further such enzymes) did not improve, so the net liver benefit is unsettled.

Magnitude: Gamma-glutamyltransferase fell by 33.4 IU/L (95% confidence interval −37.2 to −29.5) and alkaline phosphatase by 8.4 IU/L (−11.3 to −5.5); alanine aminotransferase was unchanged and aspartate aminotransferase rose by 2.3 IU/L.

Lower Total and LDL Cholesterol ⚠️ Conflicted

Melatonin lowers total and LDL cholesterol (low-density lipoprotein, the fraction that drives artery plaque), a marker class that tracks cardiovascular events. The proposed mechanism is reduced oxidative modification of lipoproteins. The evidence is a meta-analysis of eight randomized trials and a later dose-response meta-analysis of 63 randomized trials. The two disagree on which fractions move: the earlier found triglycerides fell while LDL did not, the later the reverse. The net reading is a consistent modest fall in total cholesterol, with the fraction responsible unresolved.

Magnitude: Total cholesterol fell by 18.5 mg/dL (95% confidence interval −35.3 to −1.6) in the eight-trial pool and by 7.0 mg/dL (−12.2 to −1.7) in the 63-trial pool; LDL cholesterol fell by 6.3 mg/dL (−10.5 to −2.0) in the larger analysis and triglycerides by 31.5 mg/dL (−50.7 to −12.4) in the smaller one only.

Low 🟩

Shift in Bone Turnover Around Menopause

Nightly melatonin may shift bone turnover toward formation in perimenopausal and postmenopausal women, possibly by suppressing bone-resorbing cells. Evidence is a six-month randomized trial in 18 perimenopausal women, which found no density change, and a pooled analysis of three small trials too heterogeneous to combine density results.

Magnitude: Osteocalcin, a bone-formation marker, rose by 4.97 ng/mL (95% confidence interval 3.14–6.79). The literature reports no reliable pooled figure for bone mineral density itself, because heterogeneity between the three trials forced abandonment of that analysis.

Cognitive Performance in Adults with Cognitive Impairment

Melatonin produces small gains on cognitive test scores in adults with mild cognitive impairment, likely through better sleep rather than any disease-modifying action. Evidence is a meta-analysis of eight randomized trials in 518 participants and a network meta-analysis in Alzheimer’s dementia. Trials were small and inconsistent.

Magnitude: Pooled mean difference (the average gap between treatment and control) of 1.08 points on cognitive scales overall, rising to 2.63 points in the mild cognitive impairment subgroup. Separate subgroup analyses gave 2.2 points for dosing between 20:30 and 21:00, and 2.04 points for 13–24 weeks of treatment.

Adjunct Support During Cancer Treatment

Added to chemotherapy or radiotherapy, melatonin has been associated with better one-year survival and fewer treatment toxicities. Evidence is a meta-analysis of 21 randomized trials in solid tumours. Almost all contributing trials came from one Italian group, were unblinded, and remain unreplicated independently.

Magnitude: One-year mortality relative risk 0.63 (95% confidence interval 0.53–0.74), with reduced fatigue, low white-cell counts, nausea and low platelet counts.

Speculative 🟨

Shifted Oxidative-Stress Markers

Trials report shifts in markers of oxidative damage and antioxidant defence in people with chronic disease. These markers are not validated against outcomes; no trial has linked the shifts to any clinical result.

Slowed Biological Ageing

Rodent work reports longer survival with lifelong melatonin, and higher dietary melatonin intake tracks lower mortality in one Japanese cohort. No human trial has measured ageing or lifespan; the basis is animal and observational only.

Benefit-Modifying Factors

  • MTNR1B and CYP1A2 genotype: Carriers of the common MTNR1B G-allele (a variant of the gene encoding the MT2 receptor) get a stronger receptor signal. Slow CYP1A2 metabolisers hold higher blood levels for longer, so lower doses suffice.

  • Baseline melatonin output and sleep latency: People whose own evening rise is late, weak, or absent, such as totally blind individuals and some shift workers, gain most. Those already falling asleep within 15 minutes have little room to improve.

  • Baseline blood pressure and night-time dipping: Benefit on nocturnal pressure concentrates in non-dippers, people whose pressure fails to fall overnight. Normotensive dippers show little change, so pre-treatment ambulatory monitoring predicts who responds.

  • Sex differences: Women reach higher plasma concentrations than men at the same oral dose, and oral contraceptives raise levels further by inhibiting CYP1A2. Bone and menopause-related benefits have been studied almost exclusively in women.

  • Age and pre-existing conditions: Adults over 55 with fragmented sleep respond better than healthy young adults, in whom effects are minimal. Fatty liver disease, migraine, metabolic syndrome and delirium risk each define populations where measurable benefit has been demonstrated.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Daytime Sedation, Headache and Dizziness

The commonest harms are next-day drowsiness, headache, dizziness and reduced body temperature, driven by melatonin lingering past the intended window, especially with prolonged-release forms and high doses. The evidence is a systematic review and meta-analysis of 79 trials in 3,861 adults taking 10 mg or more plus a critical review of 50 controlled studies reporting adverse events. Effects are mild, reversible on stopping, and matter mainly because they carry into driving and demanding work the next morning.

Magnitude: Adverse-event rate ratio (the event rate on melatonin divided by the event rate on placebo) 1.40 (95% confidence interval 1.15–1.69) versus placebo at doses of 10 mg or more, with no detectable increase in serious adverse events (0.88, 0.52–1.50) or in withdrawals.

Impaired Glucose Tolerance When Dosed Near Food ⚠️ Conflicted

Melatonin suppresses insulin release, so a dose taken close to a carbohydrate meal worsens the glucose response. The evidence is a randomized placebo-controlled crossover trial of 5 mg in 21 adults genotyped for the MTNR1B risk variant and a randomized crossover trial of late dinner timing. Against this, a meta-analysis of 12 trials of bedtime dosing found fasting glucose slightly improved. The net reading is that melatonin blunts insulin secretion when it overlaps with eating, while bedtime dosing away from food does not worsen fasting glucose.

Magnitude: In MTNR1B risk-allele carriers, glucose tolerance worsened by 11.7% (95% confidence interval 1.0–22.3) and first-phase insulin responsivity fell 40% (−52.4 to −24.3); non-carriers showed no significant change.

Medium 🟥 🟥

Vivid Dreams, Nightmares and Night-Time Hallucinations

Melatonin increases dream vividness and, less often, produces nightmares or hallucinations at the edge of sleep. The mechanism is presumed to be altered rapid-eye-movement sleep. The evidence is the delirium-prevention meta-analysis, in which hallucinations, nightmares and gastrointestinal upset were notably more frequent on melatonin, supported by the adverse-event systematic review. It is dose-related, resolves on stopping, and is a common reason people abandon the supplement.

Magnitude: More frequent on melatonin than on placebo across the pooled delirium-prevention trials, and more likely as the dose rises; because trials collected these as spontaneously reported events rather than as a pre-specified outcome, the literature reports no pooled incidence or effect size.

Phase Shift in the Wrong Direction from Mistimed Dosing

Melatonin shifts the body clock in opposite directions depending on when it is taken relative to a person’s own evening rise. Taken too early in the biological day it delays rather than advances the clock, producing daytime sleepiness and slower adaptation, the exact opposite of the intended effect. The evidence is the Cochrane jet-lag review, which identified mistimed dosing as a specific harm, and the dose-response meta-analysis, in which time of administration was a significant predictor of outcome.

Magnitude: Each hour earlier that the dose is given relative to intended bedtime changes the standardised effect on sleep onset latency by −0.16 (p = 0.023, where p is the probability that a result this large would arise by chance alone); the direction of the clock shift reverses when dosing falls in the wrong half of the body’s daily sensitivity window.

Raised Blood Pressure in People on Calcium-Channel Blockers

In hypertensive patients well controlled on nifedipine (a calcium-channel blocker that relaxes blood vessels), added melatonin raised rather than lowered blood pressure and heart rate over 24 hours. The mechanism is unresolved, and possibly involves melatonin opposing the drug’s vessel-widening effect. The evidence is a randomized placebo-controlled 24-hour crossover study. It is a single small trial, but it reverses the expected direction of effect and has not been refuted.

Magnitude: Mean 24-hour systolic pressure rose by 6.5 mmHg and diastolic by 4.9 mmHg versus placebo, with heart rate up by roughly 4 beats per minute, in nifedipine-treated hypertensive patients.

Low 🟥

Accidental Overdose from Mislabeled and Confectionery-Style Products

Because content frequently exceeds the label and gummies resemble confectionery, unintended high-dose exposure is a real hazard, particularly in households with children. The evidence is analytical work finding content from 83% below to 478% above label, a laboratory analysis of gummy products, and national poison-centre surveillance.

Magnitude: 260,435 pediatric melatonin ingestions were reported to US poison centres over 2012–2021, a 530% rise, with five children requiring mechanical ventilation and two deaths.

Effects on Reproductive Hormones

Melatonin suppresses reproductive signalling in seasonally breeding animals, and human data hint at shifts in sex hormones at high doses. The evidence is the critical systematic review of adverse events, which flags hormonal effects as genuine uncertainty rather than established harm.

Magnitude: Not quantified in available studies. No controlled trial has been designed with reproductive hormone concentrations as a primary endpoint in adults, so only scattered secondary measurements exist.

Lowered Seizure Threshold in Epilepsy

Case reports describe seizure worsening after melatonin in people with epilepsy, though other reports and small trials describe improvement. The evidence is the Cochrane review, which singled out epilepsy as a population that may come to harm and called for systematic study.

Magnitude: Not quantified in available studies. The signal rests on isolated case reports; no controlled trial has measured seizure frequency as a primary endpoint against placebo.

Fracture in Older Adults on Repeated Courses ⚠️ Conflicted

Next-morning unsteadiness plausibly raises fall risk. A UK primary-care cohort recorded more fractures with repeated melatonin prescriptions, while a propensity-matched cohort found none against an active comparator. The net reading is an unresolved signal confined to repeat users.

Magnitude: Adjusted hazard ratio (the ratio of event rates over the follow-up period) was 1.44 (95% confidence interval 1.01–2.04) against unexposed controls and rose only with three or more prescriptions; against a comparator group taking benzodiazepines, it was 0.78 (0.51–1.17).

Speculative 🟨

Increased Tumour Incidence with Lifelong Use

Female mice given intermittent melatonin from six months of age lived longer but developed more spontaneous tumours, prompting the investigators to advise against long-term use as a longevity intervention. The basis is animal data only.

Immune Activation in Autoimmune Disease

Melatonin stimulates immune cells such as T-lymphocytes (immune attack cells), and animal work suggests it may worsen rheumatoid arthritis severity. No human trial has tested this; the basis is mechanistic and animal work.

Risk-Modifying Factors

  • MTNR1B risk-allele carriage: Carriers of the common G-allele show markedly worse glucose handling after melatonin, while non-carriers show none. Roughly 30% of people of European ancestry carry it, making genotype the single largest metabolic risk modifier.

  • CYP1A2 activity and baseline drug load: Slow metabolisers, non-smokers, and anyone on a CYP1A2 inhibitor hold far higher melatonin concentrations, amplifying sedation and next-day carry-over. Smokers and those on inducers clear it faster and see fewer effects.

  • Baseline glucose and blood pressure: Elevated fasting glucose or an existing diabetes diagnosis raises the stakes of the insulin-suppressing effect. Controlled hypertension on a calcium-channel blocker converts an expected fall in pressure into a possible rise.

  • Sex: Women achieve higher plasma concentrations than men at identical oral doses, and combined oral contraceptives raise them further, so dose-related side effects appear at lower nominal doses in women.

  • Age and pre-existing conditions: Older adults are more vulnerable to next-morning unsteadiness and falls. Epilepsy, autoimmune disease, anticoagulant use, pregnancy and breastfeeding each shift the risk profile unfavourably.

Key Interactions & Contraindications

  • Drugs that block CYP1A2, slowing melatonin breakdown (fluvoxamine, ciprofloxacin, cimetidine, oral contraceptives): Absolute contraindication for fluvoxamine, caution for the rest; blood melatonin can rise many-fold, causing profound next-day sedation. Mitigation is complete avoidance of fluvoxamine, or a quartered dose.

  • Drugs and exposures that speed CYP1A2 up (carbamazepine, rifampicin, tobacco smoke): Caution only; melatonin is cleared faster and the expected effect is blunted or lost. Mitigation is judging by response rather than dose, with reassessment if smoking status changes.

  • Anticoagulant and antiplatelet drugs, which thin the blood (warfarin, apixaban, clopidogrel): Caution with monitoring; case reports describe a rising international normalized ratio (the standard measure of clotting time) and bleeding. Mitigation is a recheck of that measure two weeks after any change.

  • Calcium-channel blockers (nifedipine, amlodipine): Caution; blood pressure and heart rate may rise instead of fall. Mitigation is ambulatory blood-pressure readings before and four weeks after starting, with discontinuation if pressure climbs.

  • Beta-blockers, which slow the heart and lower blood pressure (metoprolol, atenolol): Beneficial rather than hazardous; these drugs suppress the body’s own night-time melatonin, and low-dose replacement improved sleep in treated hypertensive patients. No mitigation needed.

  • Sedatives and prescription sleep medications (benzodiazepines such as temazepam, the Z-drug zolpidem, the antihistamine diphenhydramine, alcohol, cannabidiol): Caution; additive sedation and next-day fall risk. Mitigation is not combining them on one night, and not driving the next morning.

  • Blood-glucose-lowering drugs (metformin, sulfonylureas, insulin): Caution; melatonin’s suppression of insulin release can oppose glycaemic control if dosing overlaps with meals. Mitigation is separating melatonin from the last carbohydrate intake by at least three hours.

  • Immunosuppressants, which damp the immune system to protect transplants (ciclosporin, tacrolimus): Absolute contraindication in transplant recipients; melatonin’s immune-stimulating action could oppose graft protection. No mitigation is available, since no safe dose or monitoring strategy is established.

  • Sedating and blood-pressure-lowering supplements (valerian, magnesium glycinate, L-Theanine, 5-hydroxytryptophan, beetroot nitrate, potassium): Caution; additive drowsiness or an excessive night-time fall in blood pressure. Mitigation is introducing one agent at a time and separating melatonin from other blood-pressure-lowering supplements by several hours.

  • Other interventions (bright-light therapy, evening blue-light blocking, shift-work schedules): Caution about timing rather than pharmacology; morning bright light and evening melatonin push the clock the same way, whereas evening bright light cancels a melatonin dose taken at the same hour.

Populations who should avoid Melatonin:

  • Pregnant or breastfeeding women, at any dose, since fetal and infant safety is unestablished
  • Solid-organ transplant recipients on immunosuppression, and people with active autoimmune disease flares
  • People taking fluvoxamine
  • People with epilepsy not under stable specialist control
  • Children and adolescents outside specialist supervision for a diagnosed sleep disorder
  • People with Child-Pugh Class C liver impairment (the most severe grade of liver failure), in whom clearance is severely reduced

Risk Mitigation Strategies

  • Starting dose of 0.3–0.5 mg rather than the retail default: Physiological doses reproduce the natural night-time rise without the next-morning residual sedation, dizziness and headache that drive the 40% excess adverse-event rate seen at 10 mg and above.

  • Separation of the dose from food by at least three hours: Taking melatonin well after the last carbohydrate-containing meal prevents the acute suppression of insulin release that worsens glucose tolerance, an effect concentrated in MTNR1B risk-allele carriers.

  • Fixed administration two to three hours before target bedtime: Consistent timing relative to the body’s own melatonin rise prevents the reverse phase shift, daytime sleepiness and delayed adaptation that mistimed dosing causes.

  • MTNR1B genotyping before regular use: A single test identifies roughly 30% of people of European ancestry who show materially worse glucose handling on melatonin, allowing them to restrict use to occasional travel rather than nightly dosing.

  • Third-party assay verification of the product: Choosing certified products guards against the 83%-below to 478%-above label variability and the serotonin contamination found in market surveys, which drive unintended overdose.

  • No driving or machinery operation the morning after a dose above 3 mg: Melatonin’s carry-over effect on alertness and reaction time is the mechanism behind next-day impairment, and it is worse with prolonged-release forms.

  • Blood-pressure and clotting-measure recheck at four weeks: Early monitoring catches the paradoxical pressure rise seen with calcium-channel blockers and the international normalized ratio drift reported with warfarin.

  • Storage out of children’s reach in child-resistant packaging: Gummy formats are the direct cause of the 530% rise in pediatric poison-centre calls, including cases requiring mechanical ventilation.

Therapeutic Protocol

  • Standard low-dose protocol: Practitioners focused on circadian timing, including the Massachusetts Institute of Technology group that defined the dose-response, use 0.3–0.5 mg taken two to three hours before target bedtime.

  • Sleep-onset protocol: Where the goal is faster sleep onset rather than phase shifting, the pooled dose-response optimum is about 4 mg taken three hours before the desired bedtime, rather than 2 mg at bedtime.

  • Competing high-dose approach: Life Extension, which also sells melatonin, argues for 10–60 mg nightly on antioxidant and anti-cancer grounds. Trials at these doses show more minor side effects without more serious ones.

  • Competing prolonged-release approach: European sleep clinics use prescription 2 mg prolonged-release melatonin nightly in adults over 55, developed by Neurim Pharmaceuticals, which sponsored its registration trials.

  • Best time of day: Evening only. Morning or midday dosing pushes the body clock the wrong way; the phase-advance window sits roughly two to five hours before habitual sleep onset.

  • Half-life: Immediate-release melatonin has an elimination half-life of about 40–60 minutes, so plasma levels are largely gone within four hours. Prolonged-release formulations extend the exposure window to roughly eight hours.

  • Single versus split dosing: A single evening dose is standard. Splitting is used only in shift-work realignment, where a small dose before the daytime sleep episode is followed by nothing further.

  • Genotype-guided dosing: Protocols for MTNR1B risk-allele carriers confine use to occasional travel or to well-fasted evenings. Slow CYP1A2 metabolisers and non-smokers are placed at the low end of any dose range.

  • Sex-based adjustment: Women, especially those on combined oral contraceptives, reach higher plasma concentrations from the same oral dose and generally need the lower half of any dose range to avoid morning carry-over.

  • Age-related considerations: Adults over 55 are the group with the clearest trial evidence and are also most vulnerable to next-morning unsteadiness, so 0.3–2 mg with an early evening dosing time is the usual compromise.

  • Baseline biomarker guidance: Ambulatory blood-pressure monitoring identifies non-dippers, who gain most on pressure; fasting glucose and HbA1c (the three-month average blood sugar) identify those for whom insulin suppression matters most.

  • Pre-existing condition adjustments: Fatty liver disease and migraine protocols use 3 mg nightly for at least 12 weeks. Delirium prophylaxis around surgery uses 3–5 mg nightly starting the evening before the procedure.

Discontinuation & Cycling

  • Intended duration: Melatonin is best framed as episodic rather than lifelong. The clearest indications, travel, shift rotation, and short realignment blocks, are self-limiting; only age-related sleep fragmentation has been trialled for a full year.

  • Withdrawal effects: No withdrawal syndrome has been documented, and doses of 0.5 mg and 50 mg did not alter the amplitude of the body’s own melatonin secretion, so output does not need to recover after stopping.

  • Rebound insomnia: Sleep typically returns to its untreated baseline rather than getting worse, which distinguishes melatonin from benzodiazepines and similar prescription sleep medications. Any perceived rebound usually reflects the original sleep problem reappearing.

  • Tapering protocol: Tapering is not required pharmacologically. Where nightly use has become habitual, stepping down over one to two weeks helps separate a genuine effect from expectation before deciding whether to resume.

  • Cycling for efficacy: Tolerance has not been demonstrated, and the sleep effect did not dissipate with continued use in pooled trials, so cycling is not needed to preserve efficacy. Some practitioners cycle anyway to limit cumulative exposure.

Sourcing and Quality

  • Third-party verification: An independent seal confirms identity and content; Nature Made carries USP Verified status and Thorne’s Melaton-3 is NSF Certified for Sport. Independent testing found only 9 of 31 products within 10% of label.

  • Synthetic over animal-derived: Pharmaceutical-grade synthetic melatonin is the only source in current commercial use. Melatonin extracted from bovine pineal glands carries a theoretical transmissible-disease risk and has been abandoned for that reason.

  • Serotonin contamination: A market analysis of 31 supplements found serotonin, a controlled substance, in 8 of them at 1–75 micrograms. Certificates of analysis that include contaminant screening, not just melatonin content, are the safeguard.

  • Avoid gummy formats: Gummies show the widest deviation from label and are the direct driver of accidental pediatric ingestions. Tablets, capsules or liquids allow accurate low dosing and are far less attractive to children.

  • Low-dose availability: Most retail products start at 3, 5 or 10 mg. Sourcing 0.3–0.5 mg products, or splitting scored tablets, is often necessary to reach a physiological dose without a compounding pharmacy.

  • Prescription formulations: In the United Kingdom, European Union and Australia, prolonged-release 2 mg melatonin is a licensed prescription medicine, manufactured to pharmaceutical standards with content uniformity that supplement regulation does not guarantee.

Practical Considerations

  • Time to effect: The sleep-onset effect appears on the first night. Phase shifting takes three to five nights. Blood pressure, liver enzyme and migraine benefits require 8–12 weeks of consistent nightly use.

  • Common pitfall of over-dosing: The most frequent mistake is treating melatonin as a sedative and escalating to 10 mg or more, which increases next-day residual sedation and impaired morning alertness without improving the timing signal it actually provides.

  • Common pitfall of mistiming: Taking it at lights-out rather than two to three hours earlier wastes most of the phase-shifting effect, and taking it too early in the day pushes the body clock in the wrong direction.

  • Common pitfall of ignoring light: Evening screen and room light suppresses the body’s own melatonin and works directly against a dose taken at the same hour, so supplementation without dim evening light delivers less than expected.

  • Regulatory status: In the United States melatonin is a dietary supplement, not reviewed for efficacy before sale. The American Academy of Sleep Medicine, whose members earn income from sleep-clinic care and prescribing, advises against it for chronic insomnia.

  • Cost and access incentives: Melatonin costs 1–60 cents per milligram, far below branded prescription sleep drugs. Insurers and health systems therefore have a financial interest in favouring it, while manufacturers of prescription sleep drugs have the opposite interest.

  • Anti-doping status: Melatonin is not on the 2026 World Anti-Doping Agency prohibited list, so competitive athletes may use it, subject to the usual contamination risk of uncertified supplements.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating, through MT1 and MT2 receptors in the master clock. Melatonin shortens sleep onset by minutes rather than hours, and works best combined with a dark bedroom, consistent wake time, and morning outdoor light. It does not consolidate sleep through the night, so early-morning waking is not a melatonin problem.

  • Nutrition: Direct and potentially adverse, through suppression of insulin release. Dosing that overlaps with carbohydrate intake carries an acute glucose penalty, which a gap of three to four hours after the last meal avoids. Pistachios, tart cherries, walnuts and oats contain melatonin, but at doses orders of magnitude below supplements.

  • Exercise: Indirect, with no evidence of blunted training adaptation. Evening dosing shortly before hard training is impractical because of drowsiness and lower core temperature, so melatonin belongs after training rather than before. Regular daytime exercise strengthens circadian amplitude and reduces the need for supplementation.

  • Stress management: Indirect and mildly potentiating. Melatonin lowers evening core temperature and increases the brain’s main calming signal, which supports wind-down routines. It does not lower cortisol directly, and it cannot substitute for reducing evening cognitive arousal, the commonest driver of difficulty falling asleep.

Monitoring Protocol & Defining Success

Before starting, a baseline set establishes where the modifiable risk sits and where benefit is plausible: fasting glucose and HbA1c (the three-month average blood sugar), because melatonin suppresses insulin release; a 24-hour ambulatory blood-pressure recording to identify non-dipping, which predicts who gains most; a liver panel where fatty liver disease is suspected; and MTNR1B genotyping before any nightly regimen. A two-week sleep diary or wearable record of sleep onset latency gives the comparator against which any benefit is judged.

Ongoing monitoring is light. Ambulatory blood pressure and, for anyone on warfarin, the international normalized ratio are rechecked at four weeks. Fasting glucose and HbA1c are repeated at three months, then every six to twelve months for continuous users. Liver enzymes are repeated at twelve weeks only where a hepatic indication prompted use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–85 mg/dL Melatonin suppresses insulin release 8–12 hour fast; conventional range extends to 99 mg/dL, which tolerates more drift than is ideal
HbA1c (glycated haemoglobin, the three-month average blood sugar) 4.8–5.2% Detects cumulative glycaemic drift from nightly use No fasting needed; conventional cut-off is 5.7%; unreliable in anaemia or recent blood loss
Nocturnal systolic blood pressure Falls 10–20% below daytime mean Non-dipping is the pattern melatonin corrects 24-hour ambulatory device; conventional care reports only clinic readings, which miss this entirely
Sleep onset latency Under 20 minutes The primary outcome melatonin is taken for Wearable or diary averaged over 14 nights; no laboratory equivalent needed
Gamma-glutamyltransferase (a liver enzyme sensitive to oxidative stress) Under 25 U/L in men, under 20 U/L in women Tracks the hepatic benefit in fatty liver disease Fasting preferred; conventional upper limits near 55 U/L are far looser than functional targets
International normalized ratio (clotting time, for warfarin users only) Within the individual’s prescribed target band Case reports describe drift after starting melatonin Check within two weeks of starting or stopping; pairs with a full blood count
Morning alertness on a validated sleepiness scale Score under 10 on the Epworth Sleepiness Scale Detects next-day carry-over, the commonest harm Self-administered; compare against the individual’s own pre-treatment score
Overnight urinary 6-sulfatoxymelatonin (the main melatonin breakdown product) No established target exists; track the change from the individual’s own pre-treatment baseline instead Estimates the body’s own night-time output Requires a full overnight urine collection; pair with a sleep diary covering the same nights

Qualitative markers matter as much as the laboratory set, and are typically logged nightly for the first month:

  • Time from lights-out to sleep, judged subjectively
  • Morning grogginess or headache on waking
  • Dream vividness, and any nightmares
  • Daytime energy and afternoon alertness
  • Cognitive clarity during the first working hours
  • Ease of waking without an alarm

Emerging Research

  • Melatonin and brain ageing: NCT03954899 is recruiting 230 adults with mild cognitive impairment, cognitive decline or healthy ageing to test 5 mg nightly, with episodic memory as the primary endpoint. It is the closest thing to a longevity-relevant cognition trial.

  • Head-to-head insomnia comparison: NCT07542756 is a Phase 4 trial at the University of Pennsylvania randomising 1,200 adults across common prescription and over-the-counter insomnia treatments, reporting relative response, tolerability and durability out to six months.

  • Cardiovascular and cancer endpoints: NCT04631341 proposes 10,000 older adults with total cancer and cardiovascular incidence as the primary endpoint. It has remained not-yet-recruiting since its listed 2021 start, so its delivery is uncertain.

  • Organ protection: NCT05084196 is a Phase 3 trial in 300 participants testing melatonin for prevention of acute kidney injury, one of the few trials putting the antioxidant hypothesis to a hard clinical endpoint.

  • Nocturnal blood pressure: NCT06380491 is a Phase 4 trial giving 3 mg for 30 days to 50 adults with obstructive sleep apnoea, measuring restoration of the normal overnight blood-pressure dip.

  • Genotype-stratified metabolic risk: Work by Qian et al., 2026 could weaken the case for nightly use by showing that harm concentrates in MTNR1B risk-allele carriers. Replication in larger, longer trials would make genotyping a precondition rather than an option.

  • Long-term safety gap: Menczel Schrire et al., 2022 found that 29 of 79 high-dose trials reported nothing at all about adverse events. Trials designed with harms as pre-specified outcomes could move the safety picture in either direction.

  • Unresolved tumour signal: The finding by Anisimov et al., 2001 that lifelong melatonin extended mouse lifespan while raising tumour incidence has never been resolved in mammals, and remains the most consequential open question for continuous use.

  • Whether output really declines with age: Zeitzer et al., 1999 found no difference in melatonin output between healthy drug-free older and younger adults, directly challenging the replacement rationale. Whether decline is ageing itself or accumulated illness remains contested.

Conclusion

Melatonin is the body’s night signal rather than a sedative, and most of what the evidence supports follows from that. It reliably shortens the time taken to fall asleep, by minutes rather than hours, and it realigns the body clock after travel or shift changes. Beyond sleep, the firmest findings are lower blood pressure during the night with slow-release forms, calmer nerves before an operation, and fewer episodes of confusion after surgery. Effects on migraine, liver markers, bone, thinking ability in people already impaired, and cancer care are weaker, thinner, or drawn from a narrow set of investigators.

The harms are mostly mild and reverse on stopping: next-morning grogginess, headache, vivid dreams. Two matter more. Melatonin blunts the release of the hormone that clears sugar from the blood, so a dose overlapping with food worsens the response, and this concentrates in people carrying a common gene variant. And products often contain far more or far less than the label states.

The evidence base carries visible interests on every side. Part of the blood-pressure work comes from the maker of the prescription version. The medical societies advising against melatonin earn their living from clinic care and prescribing. The publishers making the strongest case for large doses also sell it. Health systems have a cost reason to prefer it. None of this settles the question of whether nightly lifelong use is wise, which remains genuinely open.

Top - Benefits - Risks - Protocol